Reminder: Invitation to Roche ’s virtual Neuroscience Update IR Event
We are pleased to invite investors and analysts to participate in our virtual event onMonday,30 October2023, highlighting Roche ’s Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator). 17:00 – 18:15 CET / 16:00 - 17:15GMT12:00 – 1:15 pm EDT / 9:00 – 10:15 am PDT The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor Relati...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns
Neonatal sepsis is a leading cause of death for newbornsTesting IL-6 can indicate a neonatal sepsis infection earlier than other biomarkersEarlier diagnosis of neonatal sepsis can lead to improved outcomes and a reduction of long-term complications from sepsisBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark.*Elecsys IL-6 aids physicians in combating the impact of neonatal sepsis by facilitating an early diagnosis. Early and improved...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
Late-breaking data for Roche ’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis
New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS)More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at 8 weeksThe safety profile of fenebrutinib was consistent with previous and ongoing clinical trials across more than 2,500 people to dateBasel, 13 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from the Phase II FENopta study showing that inve...
Source: Roche Investor Update - October 13, 2023 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s 3rd Quarter Sales 2023 Webinar
Roche will publish its Sales Results for the 3rd Quarter of 2023 prior to the opening of the Swiss Stock Exchange onThursday,19 October 2023.07:00 CEST / 06:00 BST / 01:00 AM EDT / 10:00 PM PDT (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here14:00 – 15:30 CEST / 13:00 – 14:30 BST08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDTThe webinar will start with presentations by senior management,followed by a Q&A session.Presenters:Thomas Schinecker, CEO Roche GroupTeresa Graham, CEO Roche PharmaceuticalsMatt ...
Source: Roche Investor Update - October 12, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Investor Update - October 12, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Investor Update - October 11, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Investor Update - October 10, 2023 Category: Pharmaceuticals Source Type: news
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche ’s Evrysdi able to sit independently after 1 year of treatment
RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of Evrysdi treatment – without treatment these babies would never be able to sitAll babies were able to swallow and feed orally and none required permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globallyBasel, 04 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi ® (risdi...
Source: Roche Investor Update - October 4, 2023 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s virtual Neuroscience Update IR Event
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 30 October2023, highlighting Roche ’s Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator). 17:00 – 18:15 CET / 16:00 - 17:15GMT12:00 – 1:15pmEDT / 9:00 – 10:15 am PDT The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for downloadat 16:00 CET on the day of the event.>click here Access to virtual event (pre-registration requir...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s 3rd Quarter Sales 2023 Webinar
Roche will publish its Sales Results for the 3rd Quarter of 2023 prior to the opening of the Swiss Stock Exchange onThursday,19 October 2023.07:00 CEST / 06:00 BST / 01:00 AM EDT / 10:00 PM PDT (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here14:00 – 15:30 CEST / 13:00 – 14:30 BST08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDTThe webinar will start with presentations by senior management,followed by a Q&A session.Presenters:Thomas Schinecker, CEO Roche GroupTeresa Graham, CEO Roche PharmaceuticalsMatt...
Source: Roche Investor Update - September 21, 2023 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Investor Update - September 7, 2023 Category: Pharmaceuticals Source Type: news
